a total of 5 495 203 eligible subjects were included in the study. Subjects Objective-Abdominal aortic aneurysm (AAA) is a complex multifactorial disease associated with a high morbidity and mortality. Increased inflammation including T-helper 17 cell-mediated effects has been implicated in AAA pathogenesis. Psoriasis is considered to be a T-helper 17-driven chronic inflammatory disease and in view of potentially overlapping inflammatory mechanisms, we investigated the risk of AAA in patients with psoriasis in a nationwide cohort. Approach and Results-The study comprised all Danish residents aged ≥18 years followed up from January 1, 1997, until diagnosis of AAA, December 31, 2011, migration or death. Information on comorbidity, concomitant medication, and socioeconomic status was identified by individual-level linkage of administrative registers. Incidence rates for AAA were calculated and incidence rate ratios adjusted for age, sex, comorbidity, medications, socioeconomic status, and smoking were estimated in Poisson regression models. A total of 5 495 203 subjects were eligible for analysis. During the study period, we identified 59 423 patients with mild psoriasis and 11 566 patients with severe psoriasis. The overall incidence rates of AAA were 3.72, 7.30, and 9.87 per 10 000 person-years for the reference population (23 696 cases), mild psoriasis (240 cases), and severe psoriasis (50 cases), respectively. The corresponding adjusted incidence rate ratios for AAA were increased in patients with psoriasis with incidence rate ratios of 1.20 (95% confidence interval, 1.03-1.39) and 1.67 (confidence interval, 1.21-2.32) for subjects with mild and severe disease, respectively. Conclusions-In a nationwide cohort, psoriasis was associated with a disease severity-dependent increased risk of AAA.
A bdominal aortic aneurysm (AAA) is a complex multifactorial disease associated with increased morbidity and mortality. 1, 2 The prevalence of AAA increases with age and affects ≤2% of men aged ≥65 years. 3 Emerging evidence suggests that AAA is a focal representation of a systemic disease with a distinct inflammatory component, rather than a mere consequence of atherosclerosis. [4] [5] [6] [7] Chronic inflammation in the aortic wall is crucial for AAA formation, and recent evidence has shown striking similarities between central inflammatory pathways involved in AAA and those occurring in psoriasis, a prevalent chronic inflammatory disease, with apparent pivotal roles of T-helper-17 cells and interleukin-17 in both conditions. [8] [9] [10] [11] [12] In view of these overlapping inflammatory pathways and an established increased risk of atherosclerotic disease in patients with psoriasis, it seems plausible that patients with psoriasis may also have increased risk of AAA. 13, 14 Although limited case series have reported an increased risk of AAA in some other autoimmune disorders including rheumatoid arthritis and systemic lupus erythematosus, no large-scale studies have explored the potential association between AAA and psoriasis. 15, 16 Therefore, we conducted a retrospective cohort study by using Danish national registers to investigate the risk of AAA in patients with psoriasis compared with the general population.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
with a history of psoriasis (n=14 352) and AAA (n=5318) were excluded at the study start. During follow-up, we identified a total of 59 423 subjects with mild psoriasis and 11 566 with severe psoriasis. These patients were compared with the reference population of 5 404 544 individuals. During the study period, 23 986 patients were diagnosed with AAA. A flowchart of the study population is illustrated in the Figure, and baseline characteristics for the study population are presented in Table 1 .
Risk of AAA in Patients With Psoriasis
The results showed a disease-severity-dependent association between psoriasis and AAA ( Table 2 ). The overall incidence rates (IRs) of AAA were 3.72, 7.30, and 9.87 per 10 000 person-years for the reference population (23 696 cases [mean follow-up, 14.4 years]), mild psoriasis (240 cases [mean follow-up, 5.7 years]), and severe psoriasis (50 cases [mean follow-up, 5.7 years]; Table 3 ). The multivariable and time-dependent Poisson regression analyses, adjusted for age, sex, and calendar year showed increased risk of AAA in patients with psoriasis when compared with the reference population with IR ratio (IRR) of 1.36 (95% confidence interval [CI], 1.19-1.54) and IRR 2.00 (95% CI, 1.51-2.64) for mild and severe psoriasis, respectively. The risk associated with psoriasis remained significant in the fully adjusted statistical models controlling for age, sex, calendar year, comorbidity, concomitant medications, socioeconomic status, and smoking history with IRRs of 1.20 (95% CI, 1.03-1.39) for mild and 1.67 (CI 1.21-2.32) for severe psoriasis ( Table 2 ).
Sensitivity Analyses
Censoring of patients who developed atherosclerotic disease during the study and exclusion of patients with atherosclerotic disease before the study start did not alter the risk of AAA in psoriasis patients ( Table 2 ). With the use of the more liberal criteria for psoriasis, we identified 88 910 patients with mild and 23 059 patients with severe psoriasis. The results in this analysis were similar to the primary analyses with increased IRRs for AAA in patients with mild (IRR, 1.41 [95% CI, 1.26-1.57]) and severe (IRR, 1.66 [95% CI, 1.35-2.03]) psoriasis. When we adjusted for comorbidity that was continuously updated throughout the study period, the results for severe disease remained comparable with those of the primary analyses with IRR of 1.12 (95% CI, 1.00-1.27) for mild psoriasis and IRR of 1.67 (95% CI 1.21-2.32) for severe psoriasis. The additional analysis to assess the risk of AAA in patients with osteoarthritis showed no significant association (IRRs, 1.08 [95% CI, 0.99-1.18]) between these 2 diseases. In line with our primary results, supplementary analyses to estimate risk of ruptured AAA in patients with psoriasis yielded increased IRRs for mild (IRR, 1.60 [95% CI, 1.21-2.12]) and severe (IRR, 1.94 [95% CI, 1.01-3.36]) psoriasis. The IRs per 10 000 person-years of undergoing surgery for AAA were estimated to be 3.03, 7.73, and 8.09 for the reference population (n=22 455), mild psoriasis (n=254), and severe psoriasis (n=41), respectively.
Discussion
In this retrospective cohort study of the Danish population, we found an increased risk of AAA in patients with psoriasis, independent of traditional cardiovascular risk factors. Notably, the observed risk increased with increasing severity of psoriasis. The results were supported by the sensitivity analyses. To our knowledge, this is the first study to assess the risk of AAA in patients with psoriasis in a nationwide setting. These results may warrant the need for increased awareness on higher risk of AAA in patients with severe psoriasis.
Psoriasis is a chronic immune-mediated inflammatory disease associated with cardiometabolic comorbidities. 13, 14, 17, 18 Although it is well-established that psoriasis is an independent risk factor for atherosclerotic disease and persistent systemic inflammation is thought to play a contributory role, the risk of AAA in patients with psoriasis has not previously been investigated. 13, 19, 20 AAA is a common and often asymptomatic disease characterized by progressive localized dilatation of the abdominal aorta with risk of rupture and fatal outcomes. 21 Several studies have found a positive correlation between cardiovascular disease and AAA, and there is significant overlap of risk factors for atherosclerotic and AAA (eg, male sex, smoking, and a family history) with frequent coexistence of the 2 diseases. [22] [23] [24] However, the traditional view that atherosclerotic disease is the primary driving factor for the development of AAA has been reviewed, and contemporary data suggest that atherosclerosis is not the casual factor for AAA. [25] [26] [27] [28] Indeed, the pathogenesis and progression of AAA are considered to be a multifactorial process that comprises, for example, inflammation, matrix degradation, thrombosis, increased biomechanical aortic wall stress, and a host of associated mediator molecules. 1, 2, 29 Evidence has indicated that systemic levels of inflammatory markers, eg, C-reactive protein and tumor necrosis factor-α, are increased in patients with AAA and other chronic inflammatory diseases including psoriasis. 9, 30 Furthermore, a central pathogenic role for tumor necrosis factor has been suggested for both AAA and psoriasis, and more specifically, recent studies have indicated that T-helper-17 cells and interleukin-17 can be of pivotal importance in the inflammatory pathogenesis of AAA, as was established long ago for psoriasis. 8, 11, 31, 32 Also, hemodynamic forces and segmental aortic stiffening probably contribute to AAA development, and in patients with psoriasis, increased arterial stiffness is associated with systemic inflammation. 33, 34 Moreover, anti-tumor necrosis factor therapy can attenuate AAA formation in a murine model, and in subjects with psoriasis, these agents decrease aortic stiffness and endothelial dysfunction along with their amelioration of psoriatic lesions. [35] [36] [37] Taken together, these data support the notion that shared inflammatory mechanisms contribute to the psoriasis severity-dependent increased risk of AAA observed in the current study. This finding clearly requires independent replication and the clinical consequences are unclear at present, eg, whether patients with psoriasis should undergo increased ultrasonic screening for AAA, and whether anti-tumor necrosis factor and other anti-inflammatory treatment of psoriasis may reduce the risk of AAA.
Limitations and Strengths
When interpreting our findings, some limitations and strengths should be considered. Register-based follow-up studies are susceptible to changes in registration of the data over time, eg, International Classification of Diseases coding practices. However, in Danish National Patient Registry, established International Classification of Diseases codes have been used since 1978 and the Danish Health Authorities and speciality associations continuously monitor registration practices, with no major alterations or administrative changes of coding practices relevant to our study occurring during the 1997 to 2011 study period. 38, 39 Increased diagnostic activity after the diagnosis of psoriasis increases the risk of surveillance bias and such effects may not have been captured by our adjustments for important covariates including concomitant medication and comorbidity, and even in the sensitivity analyses, respectively. Moreover, we used the third hospital diagnosis as classification of severe psoriasis, and although results of our sensitivity analyses (severe psoriasis classified by first hospital diagnosis) generally were in agreement with our primary findings, the validity of hospitalization numbers for assessment of psoriasis severity has not been formally investigated. AAA is often asymptomatic and discovered incidentally as a result of screening. Of note, our group has previously validated the AAA diagnoses used in the present study with an overall predictive value of 89%. In 90% of these cases, the diagnoses were established by imaging techniques including ultrasound examination and computer tomographic scans. 40 Nevertheless, an element of residual confounding related to our approach with identification of exposures and end points based on hospital diagnoses cannot be ruled out. Also, our method of identifying mild psoriasis by the use of claimed prescriptions of vitamin D derivatives cannot be extrapolated to patients who may have received other topical therapies or ultraviolet phototherapy, in private dermatology clinics. However, we have validated this method in a previous study, where we assessed hospital records of 155 randomly selected patients, who were diagnosed with psoriasis by a hospital dermatologist. In this validation analysis, vitamin D derivatives were found to be the preferred first-line treatment for 73% of the patients with psoriasis. 41 Although the results cannot be generalized to the patients who were not captured by our criteria for mild psoriasis, these patients would have been misclassified as controls and hence bias our estimates toward the null hypothesis. Also, given the large sample size, the impact of such misclassification is likely to be small. 41 Furthermore, the registries used in the study lacked information on important clinical parameters such as smoking status. Therefore, as a proxy for smoking, we used information on diagnoses of smoking, tobacco use, chronic obstructive lung disease, lung cancer, and pharmacological treatment for smoking cessation. Although this method is likely to have captured some of the effect in the analyses, it is an indirect approximation of smoking status and the results should be interpreted accordingly. 42 Finally, the Danish population is primarily of Northern European decent, and extrapolation to other nationalities should be performed with caution. Because of the observational design of our study, we cannot determine causality.
The study strengths include use of nationwide prospectively recorded data with limited loss to follow-up, adjustment for important covariates, and use of validated measures of exposures and outcomes, respectively. The Danish tax financed healthcare system ensures free access to medical care to all citizens, which minimized the risk of selection bias attributed to, eg, age, sex, health insurance, and socioeconomic status. Also, the exclusion of subjects with a history of psoriasis and AAA at the baseline provided a more precise allocation of time at risk.
Conclusion
The results of the present study indicate a disease severitydependent increased risk of AAA in patients with psoriasis. These findings add importantly to current evidence of psoriasis as a clinically relevant risk factor for cardiovascular disease and may require increased focus on heightened risk of AAA in patients with psoriasis. Further research is warranted to delineate the mechanisms and consequences of this association. 
